Methodology

All entries for: Layoffs

October 21, 2024

Takeda

Layoffs

Cambridge, MA
10,001-50,000 employees
10001-50000 employees

“Takeda is laying off dozens of employees in Massachusetts, according to a Worker Adjustment and Retraining Notification (WARN) alert filed with the state late last week. The layoff process kicked off in late September and will run through March of next year, according to state records.

“While the WARN alert states that 79 employees across the two sites are set to face cuts, the final number “is not clear at this time” and will depend on potential “redeployment opportunities,” according to a detailed filing cited by Boston Business Journal.”

Disease Area: Multiple
Drug Type: Biologic, Small Molecule
Source
August 14, 2024

Evotec

Layoffs

Hamburg, Germany
1,001-5,000 employees
1001-5000 employees

“Evotec is having to further shrink its manufacturing footprint and has identified 400 jobs globally that could potentially get cut, with a “sizable share” set to be laid off this year, according to Wojczewski. The first round of layoffs saw 100 workers cut across the UK and US, according to the company presentation. The rest of the layoffs will be made in Germany, Italy and France, Wojczewski added.

The company has also completed the shutdown of its chemistry work at a site in Lyon, France, and is closing an API manufacturing facility in Halle, Germany.”

Disease Area: Multiple
Drug Type: Biologic, Small Molecule
Source
August 2, 2024

Vir Biotechnology

Discontinued Research, Layoffs

San Francisco, CA
201-500 employees
201-500 employees

“As part of its second-quarter business results, Vir revealed that it will no longer be continuing its work in COVID-19 and influenza, while pulling the plug on its T-cell-based viral vector platform. Instead, the biotech will restrict its virology business to its hepatitis B and D programs, allowing it to focus only on the “highest near-term value opportunities.”

“Under Vir’s strategic overhaul, the biotech will lay off 25% of its workforce, eliminating approximately 140 roles across its operations.”

“Vir now expects to close out the year with around 435 employees, which is some 200 employees fewer from its peak headcount in mid-2023.”

3 Discontinued Research Programs: COVID-19, influenza, and T-cell-based viral vector platform research programs.

Disease Area: Antiviral, Multiple, Oncology
Drug Type: Biologic, Small Molecule
Source
April 24, 2024

BioMarin

Discontinued Drug, Discontinued Research, Layoffs

San Rafael, CA
1,001-5,000 employees
1001-5000 employees

As a result of its prioritized portfolio, four programs will be discontinued, including BMN 331, BMN 255, BMN 355 and BMN 365. None of the programs were discontinued due to safety signals.

4 Discontinued Drugs: BMN 331 (biologic), BMN 255 (biologic), BMN 355 (biologic), BMN 365 (biologic)
4 Discontinued Research Programs

Disease Area: Cardiology, Chronic Disease, Multiple, Rare Diseases
Drug Type: Biologic
Source
April 22, 2024

Pfizer

Discontinued Research, Layoffs

New York, NY
50,001+ employees
50001+ employees

“Pfizer is letting go an undisclosed number of employees and ending research operations at its site in Boulder, CO, the company confirmed to Endpoints News… At one point, it employed almost 300 people, according to Pfizer’s website… The site mainly focused on small molecules for oncology, according to Pfizer’s webpage for the location.”

1 Discontinued Research Program

Disease Area: Oncology
Drug Type: Small Molecule
Source
December 5, 2023

IGM Biosciences

Discontinued Drug, Discontinued Research, Layoffs

Mountain View, CA
201-500 employees
201-500 employees

“The Company will continue to focus on the development of oncology and immunology and inflammation product candidates under its collaboration with Sanofi. In conjunction with this strategic refocusing, the Company will be reducing its workforce by approximately 22 percent…

“IGM continues to have a tremendous opportunity to transform a variety of disease areas using an entirely new class of antibody medicines,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “Although we are very encouraged by the clinical and preclinical data that we have generated for the programs we are halting, given the difficult conditions in the capital markets for our industry, we have decided to focus our capital resources on those opportunities that we believe have the most potential to produce significant near-term value. We are very sorry that some of our dedicated and talented employees will be leaving IGM as part of this strategic refocusing, and we wish to extend our sincere thanks and assistance to them in this difficult transition.”…

As a part of this strategic refocusing, the Company will halt the following clinical development activities:

Aplitabart in acute myeloid leukemia and in combination with birinapant
IGM-2644 (CD38 x CD3) in multiple myeloma
IGM-2537 (CD123 x CD3)
IGM-7354 (IL-15 x PD-L1)”

4 Discontinued Drugs: Aplitabart in acute myeloid leukemia (biologic), IGM-2644 (CD38 x CD3) in multiple myeloma (biologic), IGM-2537 (CD123 x CD3) (biologic), IGM-7354 (IL-15 x PD-L1) (biologic)
4 Discontinued Research Programs

Disease Area: Oncology
Drug Type: Biologic
Source
October 10, 2023

Pfizer

Layoffs

New York, NY
50,001+ employees
50001+ employees

“Pfizer is conducting layoffs at its Boulder, CO research facility, months after announcing a retreat from a significant chunk of its early-stage research… The facility specialized in small molecule discovery, and housed nearly 300 employees, according to Pfizer’s website.”

Disease Area: Oncology
Drug Type: Small Molecule
Source
Facebook Linkedin
Main Menu
Scroll to Top